Profile data is unavailable for this security.
About the company
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.
- Revenue in USD (TTM)0.00
- Net income in USD12.16m
- Incorporated2015
- Employees13.00
- LocationAVROBIO Inc100 TECHNOLOGY SQUARE, 6TH FLOORCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 914-8420
- Fax+1 (302) 655-5049
- Websitehttps://www.avrobio.com/
More ▼
Mergers & acquisitions
| Acquired company | AVRO:NSQ since announced | Transaction value |
|---|---|---|
| Tectonic Therapeutic Inc | -12.44% | -- |
Data delayed at least 15 minutes, as of Apr 24 2024 17:49 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics Inc | 103.00k | -51.85m | 51.21m | 23.00 | -- | -- | -- | 497.18 | -2.93 | -2.93 | 0.0055 | -0.4703 | 0.011 | -- | -- | 4,478.26 | -555.46 | -142.43 | -- | -342.79 | -- | -- | -50,336.89 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 51.28m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 52.66m | 729.00 | -- | 0.4216 | -- | 0.3054 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 52.80m | 1.00 | -- | 0.2948 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Arca Biopharma Inc | 0.00 | -5.34m | 52.93m | 4.00 | -- | 1.43 | -- | -- | -0.3704 | -0.3704 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -13.19 | -27.78 | -13.49 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -40.33m | 53.60m | 20.00 | -- | 0.627 | -- | -- | -1.82 | -1.82 | 0.00 | 3.45 | 0.00 | -- | -- | 0.00 | -44.35 | -38.44 | -47.03 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Avrobio Inc | 0.00 | 12.16m | 54.28m | 13.00 | 4.39 | 0.5703 | 4.25 | -- | 0.2756 | 0.2756 | 0.00 | 2.12 | 0.00 | -- | -- | 0.00 | 11.86 | -45.22 | 13.10 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Gain Therapeutics Inc | 55.18k | -22.27m | 54.98m | 29.00 | -- | 4.37 | -- | 996.46 | -1.74 | -1.74 | 0.0042 | 0.7761 | 0.0026 | -- | 0.2544 | 1,902.76 | -104.28 | -- | -132.41 | -- | -- | -- | -40,354.33 | -13,827.07 | -- | -- | 0.0432 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Intensity Therapeutics Inc | 0.00 | -11.86m | 55.52m | 5.00 | -- | 4.22 | -- | -- | -0.8653 | -0.8653 | 0.00 | 0.9601 | 0.00 | -- | -- | 0.00 | -110.62 | -- | -254.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Enzo Biochem Inc | 32.80m | -23.31m | 55.84m | 179.00 | -- | 0.7776 | -- | 1.70 | -0.4699 | 0.6708 | 0.6586 | 1.40 | 0.3738 | 1.61 | 4.10 | 183,257.00 | -26.56 | -12.21 | -39.50 | -15.79 | 42.17 | 37.09 | -71.07 | -18.76 | 2.89 | -- | 0.0476 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -77.39m | 55.98m | 8.00 | -- | 0.6318 | -- | -- | -2.52 | -2.52 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -71.78 | -- | -81.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Kronos Bio Inc | 6.29m | -112.67m | 57.09m | 62.00 | -- | 0.352 | -- | 9.08 | -1.95 | -1.95 | 0.1089 | 2.70 | 0.0248 | -- | -- | 101,419.40 | -44.34 | -35.47 | -48.77 | -37.14 | -- | -- | -1,791.87 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Benitec Biopharma Inc | 61.00k | -21.81m | 57.22m | 18.00 | -- | 1.15 | -- | 938.09 | -10.90 | -10.90 | 0.0304 | 5.97 | 0.0037 | -- | 1.01 | 3,388.89 | -131.16 | -83.43 | -174.32 | -98.77 | 172.13 | 96.86 | -35,754.10 | -468.04 | -- | -5,423.00 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
Data as of Apr 24 2024. Currency figures normalised to AVROBIO Inc's reporting currency: US Dollar USD
31.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Dec 2023 | 4.00m | 8.92% |
| Newtyn Management LLCas of 31 Dec 2023 | 2.73m | 6.10% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.59m | 3.54% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 1.45m | 3.24% |
| Aisling Capital Management LPas of 31 Dec 2023 | 1.01m | 2.25% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 758.94k | 1.69% |
| Ikarian Capital LLCas of 31 Dec 2023 | 718.26k | 1.60% |
| Vazirani Asset Management LLCas of 31 Dec 2023 | 650.00k | 1.45% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 569.32k | 1.27% |
| Citadel Advisors LLCas of 31 Dec 2023 | 515.22k | 1.15% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
